Therefore, we propose that IFI16 may serve as a potential prognostic marker for ccRCC patients, especially those in advanced stages, and could be a potential therapeutic target for ccRCC patients. The gene discussed is IFI16; the disease is nonpapillary renal cell carcinoma.